Back to search results

Long-term Outcomes in Juvenile Mycosis Fungoides and Lymphomatoid Papulosis

This study is looking at the long-term health and experiences of people who were diagnosed with juvenile-onset mycosis fungoides (jMF) or lymphomatoid papulosis (lyp) before age 20. Researchers want to understand how these conditions affect people over time, including how long people live and how active their disease is. They also want to learn about the treatments people received and any other health issues they might have. This is an observational study, meaning researchers will follow participants and collect information without giving any new treatments. They plan to include 100 participants. The main goal is to track safety and any side effects for about one year.

Study design
This is an observational study with a planned enrollment of 100 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06207812

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

Recruiting
Not specifiedAges 18+Observational
M.D. Anderson Cancer Center
~100 participants
Updated 2026-07-16 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Lymphomatoid Papulosis
Mycosis Fungoides

Explore related trials

Lymphomatoid PapulosisMycosis Fungoides

NCT06207812

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • MD Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Julia Dai, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Julia Dai, MD
[email protected]
(713) 515-7961
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

To be eligible, participants had to be diagnosed with jMF or lyp before age 20. In the case of participants below the age of 18, parents and not the children will be contacted for participation (children are exempt from participation as their parents may answer our study questions).

Exclusion

Participants older than 20 years of age at diagnosis

What this trial measures

  • Safety and adverse events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)